It has been more than a year since Bollywood’s legendary actress Sridevi passed away in a tragic incident. Sridevi‘s death shattered the whole country, especially the Hindi film industry. Her last film before her death – MOM was released in China on Friday and it has earned a whopping amount of Rs. 11.47 crore on its opening day.
Taking to Twitter, film critic and trade analyst Taran Adarsh tweeted, “Mom debuts at No 4 position at #China BO
Take a look:
#Mom debuts at No 4 position at #China BO
#AndhaDhun>... Although the start is good, the biz needs to witness an upturn on Sat and Sun for a healthy weekend total... Fri $ 1.64 million <₹ 11.47 cr>. Note: Includes screenings held earlier. — taran adarsh (@taran_adarsh) May 11, 2019
Â
MOM's producer Boney Kapoor, who is also the husband of late actress Sridevi, got emotional as the film released in China's theatres. In a statement, Boney Kapoor said, "MOM is very close to our heart and we are very overwhelmed to witness the love the film is receiving in China... At such occasion, I wish Sri was here to see the huge success her film has garnered."
RELATED
MOM is a revenge drama which tracks the story of Janki (Sridevi), who takes revenge for her daughter Arya's (played by Pakistani actress Sajal Ali) sexual assault. The film earned around Rs 20 crore at India box office in the first week of its release.
Zee Studios released MOM in China.
Back in 2017, in an interview with Rediff, Sridevi opened up about her character in MOM. “It’s a simple story. It’s an emotional, family subject. The reason I did this film is the relationship between the mother and daughter. That really moved me. I had a good feeling about this script. I always go by instinct. I lived my Mom character. I became Devaki. I felt what she was going through. It was very unnerving to be in that kind of situation,†she had said.
It is to be noted that the demand for Indian films has witnessed a comprehensive growth in China in last three years. Many Indian films like Dangal, PK, Secret Superstar, Hichki, Sultan and others have received an overwhelming response in China.